Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

Jose A Hidalgo1,2
Celeste M Vinluan1,3
Nishaal Antony3
1UTEP/UT Austin Cooperative Pharmacy Program, College of Health Sciences, University of Texas at El Paso, El Paso, 2Department of Pharmacy, College of Pharmacy, The University of Texas at Austin, Austin, 3Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA

Abstract: There has been greater interest in developing additional antimicrobial agents due to the increasing health care costs and resistance resulting from bacterial pathogens to currently available treatment options. Gram-negative organisms including Enterobacteriaceae and Pseudomonas aeruginosa are some of the most concerning threats due to their resistance mechanisms: extended-spectrum beta-lactamase production and Klebsiella pneumoniae carbenapemase enzymes. Ceftazidime is a third-generation broad-spectrum cephalosporin with activity against P. aeruginosa and avibactam is a novel nonbeta-lactam beta-lactamase inhibitor. Avycaz®, the trade name for this new combination antibiotic, restores the activity of ceftazidime against some of the previously resistant pathogens. Avycaz was approved in 2015 for the treatment of complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections with the addition of metronidazole in patients with little to no other treatment options. This review article assesses the clinical trials and data that led to the approval of this antibiotic, in addition to its spectrum of activity and limitations.

Keywords: ceftazidime/avibactam, Avycaz, complicated urinary tract infections, complicated intra-abdominal infections

Introduction

Increasing resistance to currently available antimicrobial agents has prompted a renewed interest in developing additional agents. According to the World Health Organization’s (WHO) Global Report on Surveillance, five out of six WHO regions reported >50% resistance of Escherichia coli against third-generation cephalosporins and six out of six WHO regions reported equivocal resistance rates of Klebsiella pneumoniae against third-generation cephalosporins.1 Within the hospital setting, there has been increasing rates of resistance against some of the most common pathogens that cause complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs), which have resulted in longer lengths of stay and increased hospital costs.2

According to the United States Centers for Disease Control, some of the most concerning threats to antibiotic resistance include carbapenem-resistant Enterobacteriaceae, extended-spectrum beta-lactamase-producing Enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa.3 These gram-negative organisms are responsible for several infections including cIAIs and cUTIs. The mechanism of resistance of Enterobacteriaceae species and P. aeruginosa is primarily caused by their production of extended-spectrum beta-lactamases and carbapenemases.
of extended-spectrum beta-lactamases and *K. pneumoniae* carbapenemase (KPC) enzymes. The production of these enzymes renders the current beta-lactamase inhibitors ineffective against these resistant gram-negative pathogens.\(^{3,4}\)

Before ceftazidime/avibactam, the primary drug of choice for KPC infection was polymyxin, which has been known to have a severe side effect profile.\(^3\)

Ceftazidime/avibactam (Avycaz\(^\text{®}\)) is a combination cephalosporin and beta-lactamase inhibitor that was approved in February 2015.\(^6\) The presently available beta-lactamase inhibitors are ineffective against Ambler Class A carbapenemases and Class C enzymes.\(^7\)–\(^9\) Avibactam, formerly known as NXL104, is a nonbeta-lactam beta-lactamase inhibitor that has potent activity against most Ambler Class A enzymes, which include narrow and extended-spectrum beta-lactamases and some carbapenemases, Ambler Class C enzymes, which include extended spectrum cephalosporinas, and some Class D enzymes, which include carbapenemases.\(^10\) In this article, the clinical microbiology, pharmacology, and the most recent clinical data on ceftazidime/avibactam (two Phase I, two Phase II, and Phase III trials)\(^11\)–\(^15\) are discussed.

**Clinical microbiology**

Avibactam has activity against extended-spectrum beta-lactamases, including *K. pneumoniae*-producing carbapenemases, Class A enzymes, and extended-spectrum cephalosporinas that contain the *AmpC* gene, which are Class C enzymes.\(^16\) Avibactam also has some activity against carbapenemases produced from the OXA gene, which are Class D enzymes. Ceftazidime has broad-spectrum activity against gram-negative bacteria including *P. aeruginosa*. Consequently, the addition of avibactam to ceftazidime increases the spectrum of activity to organisms that produce beta-lactamases enzymes.\(^17\) It is important to recognize that the addition of a beta-lactamase inhibitor does not increase activity against anaerobic organisms, in contrast to other combination beta-lactam/beta-lactamase inhibitors.

The antimicrobial activity of ceftazidime/avibactam was tested against gram-negativa bacilli that were collected from 73 medical centers throughout the US.\(^18\) The results of the study confirmed that the combination of ceftazidime/avibactam had potent activity against KPC-producing Enterobacteriaceae and meropenen-nonsusceptible *P. aeruginosa*, both of which are resistant to currently available beta-lactamase inhibitors (clavulanic acid, tazobactam, and sulbactam).\(^19\)

The in vitro antibacterial activity of ceftazidime/avibactam against a panel of clinically isolated *P. aeruginosa* strains was evaluated to determine the clinical utility of this combination. The minimum inhibitory concentration (MIC) is a diagnostic laboratory test used to determine the susceptibility of pathogenic microorganisms to antibiotics. The MIC is determined by the minimum concentration of an antibiotic that inhibits visible growth overnight.\(^19\) When tested in comparison to other available beta-lactams, the addition of avibactam was effective in lowering the MIC for aztreonam, piperacillin, and imipenem. However, the addition of avibactam to ceftazidime resulted in the largest increase in activity from the 126 *P. aeruginosa* strains collected between 2006 and 2007. Only 65% of isolates were susceptible to ceftazidime alone, but 94% were susceptible to the combination of ceftazidime/avibactam.\(^16\)

The activity of ceftazidime/avibactam was also tested against Enterobacteriaceae and *P. aeruginosa* isolates that expressed beta-lactamase genes. The addition of avibactam to ceftazidime resulted in a fourfold to 512-fold reduction in the MIC of the isolates with beta-lactamase genes, compared to avibactam alone.\(^20\) However, there were three isolates that demonstrated no change in MIC upon the addition of avibactam to ceftazidime. The first isolate was from an *E. coli* strain containing the *bla*\(^\text{TEM}\) gene, in which the MIC remained unchanged when tested against ceftazidime and ceftazidime/avibactam. The second was a *P. aeruginosa* isolate containing the *bla*\(^\text{VIM}\) gene, which is a Class B metallobeta-lactamase to which avibactam had no effect. The third exception was a *P. aeruginosa* isolate with the *bla*\(^\text{OXA-23}\) gene, a member of the Class D carbapenemase-producing class, hence its resistance was unlikely to be caused by beta-lactamase as this class is unable to hydrolyze extended-spectrum cephalosporins, such as ceftazidime.\(^20\) One study has determined that ceftazidime/avibactam is effective against *P. aeruginosa* strains that contain a derepressed *AmpC* gene, which is intrinsically resistant to ceftazidime.\(^21\) These strains were incubated in fixed concentrations of avibactam along with increasing ceftazidime concentrations. The frequency of resistance to ceftazidime/avibactam was low in the three strains that were challenged. Additionally, the authors suggested that the risk of developing spontaneous resistance to the ceftazidime/avibactam combination was low as their findings revealed that the rate of resistance was lower when compared to meropenem or imipenem.\(^21\)

A previous study has described the extensive microbiology activity of ceftazidime/avibactam, but until recently there have been no KPC-producing *K. pneumoniae* isolates that have been reported to be resistant to the drug. One case report has been published that documented the first case of
resistance to ceftazidime/avibactam in a KPC-3-expressing K.
pneumoniae isolate.11 The carbapenem-resistant K. pneumo-
niae isolate was resistant to aztreonam, tobramycin,
carbapenems, ampicillin/sulbactam, extended-spectrum
cephalosporins, piperacillin/tazobactam, and ciprofloxacin.
The isolate was also resistant to doxycycline, minocycline,
chloramphenicol, and tigecycline. The exact mechanism of
resistance for this KPC K. pneumoniae isolate to ceftazidime/
avibactam is uncertain and is under investigation. Despite the
introduction of these enzymes are uncommon, the previous
example of resistance warrants increased monitoring and
surveillance for these isolates.11

Pharmacokinetics
Ceftazidime/avibactam is available as an intravenous (IV)
formulation. The components of ceftazidime/avibactam are
formulated in a 4:1 ratio containing 2,000 mg of ceftazi-
dime and 500 mg of avibactam.22 The pharmacokinetics of
both ceftazidime and avibactam are similar, in which their
individual properties remain unchanged when both are
coadministered. Ceftazidime and avibactam follow two-
compartment linear kinetics with their maximum plasma
concentration (Cmax) and area under the curve increasing
linearly with additional and higher doses. Both components
of ceftazidime/avibactam are minimally protein bound with
<10% plasma protein binding.11 Ceftazidime (80%–90%
of the dose) and avibactam are not metabolized and are pri-
marily renally excreted in their unchanged form; the renal
clearance for ceftazidime and avibactam is 115 mL/min and
158 mL/min, respectively.6 In patients with normal renal
function, the half-life (t1/2) for each component is relatively
similar: 2.76 hours and 2.71 hours for ceftazidime and
avibactam, respectively.6

Chemical structure
The basic structure of cephalosporins comprises of a four-
member β-lactam ring and a six-member dihydrothiazine
ring. Different side chain substitutions at the three and
seven positions have yielded the manufacture of several
antibiotics in the cephalosporin class.23 Ceftazidime
contains a pyridinium group at position 3 that increases
activity against P. aeruginosa and its water solubility.23,24
At position 7, the aminothiadiazole ring provides activity
against gram-negative bacilli, while the carboxypropyl-
oximino group enhances its activity toward P. aerugi-
nosa and increases its stability against beta-lactamase;
however, it also consequently reduces its activity against
Enterobacteriaceae.25–27 Avibactam is categorized into a
new class of nonbeta-lactam beta-lactamase inhibitors,
diazabicyclooctanes (DBOs).17

Indications and usage
Current clinical indications for ceftazidime/avibactam include
the treatment of patients 18 years or older with cIAIs and
cUTIs.5 However, there are ongoing clinical studies that are
investigating additional indications for the use of ceftazidime/
avibactam. Full results from the Phase III trials and future
studies are likely to expand the use of ceftazidime/avibactam
to include hospitalized adults with nosocomial and ventilator-
associated pneumonia, hospitalized pediatric patients aged
3 months to 18 years with cIAIs, and cystic fibrosis patients
with resistant respiratory P. aeruginosa infections.12,28,29

Clinical pharmacology
Ceftazidime/avibactam consists of an antibacterial beta-
lactam, ceftazidime, and a beta-lactamase inhibitor, avibac-
tam. Ceftazidime is a beta-lactam that exhibits bactericidal
activity by inhibiting cell wall synthesis by binding to
penicillin-binding proteins, resulting in bacterial cell
death.30,31 Avibactam binds covalently to beta-lactamases at
the active site, but this simple mechanism does not involve a
rearrangement that other inhibitors with a beta-lactam moiety
undergo after the opening of the four-membered beta-lactam
ring.37 Avibactam is from a group of beta-lactamase inhibi-
tors called DBOs, which are more potent when compared
to the prototypical beta-lactam ring structure. For example,
a significant amount of tazobactam and clavulanic acid is
required to inhibit one beta-lactamase molecule, compared
to only one to five molecules of avibactam.17 The increased
efficiency and activity of the DBO molecule are due to the
ring opening and being stabilized by residues that are close to
the active site, causing polar interactions. In contrast, the
opening of the four-ring beta-lactam structure undergoes
rearrangement upon the opening of the ring, resulting in
destabilization. This mechanism of reaction allows for a
more efficient inhibition and broadens the activity against
bacteria that would normally degrade ceftazidime.17

Clinical trials
Phase I studies
Two Phase I randomized, double-blinded, placebo-controlled
studies were done to evaluate the safety, tolerability, and
pharmacokinetics of avibactam both alone and in combina-
tion with ceftazidime.22 Subjects were included if they were
healthy males aged 18 years to 45 years of age, had a body
mass index of 18–27 kg/m2, negative serology for HIV,
Limitations

Intervention

Intervention

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 54.70.40.11 on 02-Apr-2018
For personal use only.

Abbreviations:

Note:

Table 1 Comparison of safety and efficacy data of Phase II cUTI and Phase II cIAI trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Primary pathogen isolated</th>
<th>Median duration of treatment</th>
<th>Most common AEs</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase II (cUTI)¹⁴</td>
<td>Ceftazidime/avibactam 500 mg/125 mg IV q8h, imipenem/cilastatin 500 mg IV q6h</td>
<td>Favorable clinical response: 24/28 (85.7%)</td>
<td>E. coli 25/27 isolates (92.6%)</td>
<td>Headache, abdominal pain, constipation, and anxiety</td>
<td>Formal sample size calculation not performed and not powered to demonstrate noninferiority to comparator</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E. coli 33/35 isolates (94.3%)</td>
<td>Dizziness, injection/infusion site reaction, abdominal pain/distension, and anxiety</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5 days (ceftazidime/avibactam)</td>
<td>Vomiting, nausea, abdominal pain, and pyrexia</td>
<td>Study not statistically powered to demonstrate noninferiority to comparator</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 days (imipenem/cilastatin)</td>
<td>Pyrexia, wound secretion, nausea, and vomiting</td>
<td></td>
</tr>
<tr>
<td>Phase II (cIAI)¹³</td>
<td>Ceftazidime/avibactam 2,000 mg/500 mg IV q8h plus metronidazole 500 mg IV q8h, meropenem 1,000 mg IV q8h plus placebo infusion</td>
<td>Favorable clinical response: 80/87 (92%)</td>
<td>E. coli 105/105 isolates (100%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6.5 days (meropenem)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Data from Lucasti et al.¹³ and Vazquez et al.¹⁴

Abbreviations: AEs, adverse effects; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; E. coli, Escherichia coli; IV, intravenous; q8h, every 8 hours.

Hidalgo et al

Drugs Design, Development and Therapy 2016:10

For personal use only.
In one Phase II randomized, double-blinded, active-controlled trial, the safety and efficacy of ceftazidime/avibactam plus metronidazole compared to meropenem was evaluated in 203 hospitalized patients with cIAIs. Patients with a confirmed diagnosis of cIAI that required surgical intervention and antibiotics were enrolled and randomized in a 1:1 ratio. Patients received either a combination dose of ceftazidime 2,000 mg plus avibactam 500 mg administered IV over 30 minutes every 8 hours plus a separate infusion of metronidazole 500 mg administered over 1 hour every 8 hours, or meropenem 1,000 mg every 8 hours plus an infusion of placebo over 1 hour (Table 1). The primary end point of the study was clinical response at the test of cure (TOC) visit, 5 days to 14 days after treatment. Patients were eligible to participate if they were aged 18 years to 90 years with a cIAI requiring surgical intervention and antibiotics. The diagnoses that were accepted included diverticular disease with perforation or abscess, secondary peritonitis, intra-abdominal abscess with intraperitoneal involvement, cholecystitis with gangrenous rupture, or acute gastric or duodenal perforation. Patients were excluded if they had small bowel obstruction or ischemic bowel without perforation, abdominal wall abscess, or other coexisting infections that would interfere with the analysis of the study. Patients were also excluded if they had previously received antibiotic therapy within 72 hours of study therapy, abnormal liver function defined as aspartate transaminase greater than three times the upper limit of normal, or an infection caused by a pathogen with resistance to the study medication. Further exclusion criteria included patients with infections of the female genitalia or perinephric infections, survival anticipated to be less than the study period, sepsis with shock not responsive to IV fluids, APACHE II score >25, or renal dysfunction defined as creatinine clearance (CrCl) <50 mL/min. Continued exclusion criteria included hematological or metastatic malignancy requiring chemotherapy, chronic cirrhosis or hepatitis, body mass index >45 kg/m², absolute neutrophil count <1,500 cell/mm³ (unless associated with infection), or immunocompromised status defined as HIV with AIDS or CD4+ T-lymphocyte count <2,000 cells/mm³. The final exclusion criteria included patients with a hemoglobin level <10 g/dL, platelet count <100,000 cells/mm³, splenectomy or chronic corticosteroid therapy defined as >20 mg of prednisone daily, patients who required additional systemic antibiotic therapy, and patients with 5 days to 14 days of therapy that were deemed unlikely to respond to treatment. A total of 87 patients in the ceftazidime/avibactam plus metronidazole group and 90 patients in the meropenem group were clinically evaluable (CE). There were 68 and 76 patients who were microbiologically evaluable (ME), with a median duration treatment time of 6 days and 6.5 days in the ceftazidime/avibactam plus metronidazole and meropenem groups, respectively. In the ceftazidime/avibactam plus metronidazole and meropenem groups, a clinical response was seen in 92% and 94.4%, respectively, in the CE subgroup and 91.2% and 93.4%, respectively, in the ME subgroup at TOC. The authors of the study concluded that there was no relationship between APACHE II scores at baseline and treatment outcome. However, it should be noted that the number of patients with an APACHE II score >10 was limited to 12 and eleven patients in the ceftazidime/avibactam plus metronidazole and meropenem group, respectively. Furthermore, response rates appeared to be similar between the two groups, independent of whether the infection was monomicrobial or polymicrobial in nature.

A small prospective, randomized, investigator-blinded, Phase II trial compared the efficacy, safety, and tolerability of ceftazidime/avibactam and imipenem/cilastatin in adults who were hospitalized with a severe cUTI resulting from a gram-negative pathogen. This trial recruited patients from 26 different centers located throughout five countries. Patients included in the study were randomized to receive either ceftazidime 500 mg plus avibactam 125 mg infused IV over 30 minutes every 8 hours or cilastatin/imipenem 500 mg infused IV over 30 minutes every 6 hours. The median duration of therapy was 5 days in the ceftazidime/avibactam group and 6 days in the cilastatin/imipenem group. The primary end point of the study was a positive microbiological response in the ME patients at the TOC visit, which was 5 days to 9 days after the last dose of therapy. The secondary end point of the study was a microbiological response in the ME patients at the end of IV therapy and late follow-up visit (LFU), 4 weeks to 6 weeks after therapy. Patients included if they were between the ages of 18 years and 90 years and were diagnosed with acute pyelonephritis or cUTI caused by a gram-negative pathogen that was deemed to be a serious infection requiring parenteral therapy. Acute pyelonephritis was defined to include patients who were febrile (oral body temperature >37.8°C) with the presence of chills beginning 12 hours into the study, pyuria, flank pain, and positive urine culture with ≥10⁵ CFU/mL caused by a pathogen with a known susceptibility to the study drugs. Patients with cUTIs were defined by having signs and symptoms that were consistent with a UTI. This included an oral body temperature >37.8°C, suprapubic pain, nausea/vomiting, dysuria, frequency, urgency, incontinence, costovertebral angle tenderness, and a positive urine culture.
with ≥10^5 CFU/mL caused by a pathogen with known or considered susceptibility to the study drugs. Patients were excluded if they had previously received at least one dose of another systemic antibiotic 48 hours before the admission urine culture, if the cUTI was caused by a pathogen with known resistance to any of the study drugs, full obstruction of the urinary tract, fungal UTI, presence of vesicoureteral reflux or ileal loops, pregnant or breast-feeding women, patients with a known history of hypersensitivity to the study medications, patients with permanent indwelling catheter, and patients believed unlikely to survive the study trial period.

The CE population had a favorable clinical response in all patients at the end of IV therapy. A favorable clinical response among the CE population at the TOC visit was observed in 24/28 (85.7%) of the ceftazidime/avibactam group and 29/36 (80.6%) in the imipenem/cilastatin arm. Results for these positive clinical outcomes are presented in Table 1. In the ME population, there was a 70.4% and 71.4% positive clinical response at TOC visit, 96.2% and 100% positive clinical response at the end of IV therapy, and a 57.7% and 60% positive response at the LFU visit in the ceftazidime/avibactam and imipenem/cilastatin groups, respectively. Comprehensively in the ME population, there was a positive microbiological and clinical response in 66.7% and 60% of patients at the TOC visit and 53.8% and 60% at the LFU visit in the ceftazidime/avibactam and imipenem/cilastatin groups, respectively. The authors of the study noted that despite the small sample size, six of seven patients (85.7%) and nine of eleven patients (81.8%) in the ME group who had a ceftazidime-resistant pathogen at the TOC visit showed a positive microbiological response with ceftazidime/avibactam and imipenem/cilastatin, respectively.14

### Phase III studies

Results from two new Phase III trials, RECLAIM-1 and RECLAIM-2, were only available in abstract form. The two studies were analyzed as one dataset and were conducted in patients with cIAIs that compared ceftazidime/avibactam plus metronidazole to meropenem.15,32 Both studies used the randomization of ceftazidime 2,000 mg plus avibactam 500 mg every 8 hours and metronidazole 500 mg every 8 hours or meropenem 1,000 mg every 8 hours. However, the ceftazidime/avibactam infusion was changed to 2 hours compared to the 30 minutes that was conducted in the Phase II trial.14 The primary efficacy end point of the RECLAIM study was clinical response at the TOC visit, which was assessed at 28 days to 35 days after randomization. The study randomized a total of 1,066 patients, and the subjects were followed after a period of 2 years. The overall cure rate was achieved in 82% patients receiving ceftazidime/avibactam and 85% for meropenem (95% CI: –8.6 to 1.6), showing noninferiority between the two treatments.13,32 Results from this Phase III cIAI trial showed meropenem had decreased mortality compared with ceftazidime/avibactam plus metronidazole (1.5% versus 2.5%, respectively).6 Clinical cure rates were reduced in patients with moderate renal impairment (CrCl 30–50 mL/min) who received ceftazidime/avibactam compared to those patients who received meropenem, 45% and 74%, respectively. Within this group of patients with a CrCl 30–50 mL/min, death occurred in 25.8% of participants who received ceftazidime/avibactam plus metronidazole compared with 8.6% of participants who received meropenem, which may be attributed to participants receiving a 33% lower daily dose than is recommended.6,32 This difference in clinical cure rates was not seen in patients with a normal renal function or mild renal impairment (CrCl >50 mL/min), suggesting insufficient dosing may have caused the lower cure rates.15

### Adverse drug reactions

Based on Phase I and Phase II trials, ceftazidime/avibactam is generally well tolerated. All subjects completed the study with no patients requiring discontinuation from the study due to adverse effects (AEs). There were six TEAEs reported in four subjects in the single ascending dose arm of the study. Only one AE was considered moderate in intensity and it resolved spontaneously while the others were considered only mild in intensity. The TEAEs that were considered related to the therapy included: postural dizziness, anxiety, abdominal pain, somnolence, and sense of oppression. In the multiple ascending dose arm, the only TEAE observed was a moderate hematoma at the injection site.22 The AEs reported from the two Phase II trials also indicated that ceftazidime/avibactam was well tolerated when compared with meropenem and imipenem/cilastatin for cIAI and cUTI.13,14 Observations of AEs were reported in 64.4% of patients who received ceftazidime/avibactam plus metronidazole, compared to 57.8% of patients who received meropenem. The most common TEAEs reported were an increased frequency of vomiting (13.9%), nausea (9.9%), pyrexia (8.9%), and abdominal pain (7.9%) in the ceftazidime/avibactam plus metronidazole group. However, most of the AEs were mild to moderate in intensity. In a separate Phase II study, 67.6% of patients in the ceftazidime/avibactam group and 76.1% of patients in the imipenem/cilastatin group reported AEs. Based on 68 subjects in the group receiving
ceftazidime/avibactam, the most common TEAE included a headache (19.1%), abdominal pain (14.7%), constipation (10.3%), anxiety (10.3%), and diarrhea (8.8%).

Drug interactions
Ceftazidime/avibactam retains its clinical efficacy when exposed to levels of pulmonary surfactant that would otherwise inhibit the bactericidal effects of daptomycin. As well, there have been no known antagonistic effects of ceftazidime/avibactam when used in conjunction with other antibiotics for the treatment of nosocomial-associated pneumonias. However, avibactam, in vitro, is a substrate of OAT1 and OAT3 transporters. The coadministration of probenecid with avibactam resulted in the inhibition of ~56% to 70% of the uptake of avibactam. Therefore, the coadministration of ceftazidime/avibactam and probenecid is not recommended. Furthermore, administration with oral contraceptive pills is not recommended due to decreased intestinal uptake of estrogen causing subtherapeutic levels of estrogen.

Contraindications
Contraindications for the use of ceftazidime/avibactam include known severe hypersensitivity reactions to Avycaz, ceftazidime, avibactam, or other members of the cephalosporin class.

Warnings and precautions
Hypersensitivity and skin reactions, *Clostridium difficile*-associated diarrhea, and central nervous system adverse reactions that were more prevalent in renally impaired patients, are concerns with ceftazidime/avibactam. Possible development of drug-resistant bacteria should also be recognized with use of ceftazidime/avibactam. In the Phase III cIAI trial, patients with a baseline CrCl of 30 mL/min to 50 mL/min demonstrated a lower clinical response to ceftazidime/avibactam. CrCl should be monitored, and the dose should be adjusted accordingly in patients with changing renal function.

Special populations
This formulation has not been studied and is not currently approved for patients younger than 18 years of age. The dose and/or interval of ceftazidime/avibactam should be adjusted in patients with renal impairment (CrCl <50 mL/min based on the Cockcroft and Gault formula). Cephalosporins as a class are considered pregnancy risk category B and ceftazidime is excreted in breast milk. It is unknown if avibactam is excreted in breast milk.

Conclusion
Clinicians have fewer antibiotic options to treat patients as drug-resistant gram-negative pathogens continue to rise. The introduction of avibactam, a nonbeta-lactam beta-lactamase inhibitor, acts differently than other beta-lactamase inhibitors and broadens the activity against bacteria that would normally degrade ceftazidime such as Amp C beta-lactamases, carbapenemase-producing *Enteria bacteria gene*, and multidrug resistant *Pseudomonas aeruginos*. Ceftazidime/avibactam is currently only indicated for use in patients with cIAIs (in combination with metronidazole) and cUTIs, including pyelonephritis, and should be reserved for patients who have no alternate treatment options because of antibiotic resistance. Judicious use of antibiotic stewardship should be used when using this medication to prevent the incidence of drug resistance. Ceftazidime/avibactam has been shown to be well tolerated in several clinical trials, with only mild-to-moderate intensity AEs reported. Future indications and resistance mechanisms remain to be seen. However, the broad spectrum of activity that ceftazidime/avibactam provides is an important advancement in the treatment of patients with cUTIs and cIAIs with limited treatment options.

Acknowledgment
Celeste M Vinluan is currently affiliated with West Coast University at the time of publication.

Disclosure
The authors report no conflicts of interest in this work.

References


